Takeda Faces $885 Million Antitrust Verdict for Delaying Generic Constipation Drug Amitiza
核心洞察
A U.S. jury found Takeda Pharmaceutical (搜索) liable for $885 million in damages for delaying generic competition of constipation (搜索) drug Amitiza through an anticompetitive scheme.
The verdict marks the first time a pharmaceutical company has been found liable by a jury in class action litigation over pay-for-delay agreements since the 2013 Supreme Court ruling.
Under federal antitrust law, the $885 million award could be automatically tripled to several billion dollars, representing a significant financial penalty for the Japanese drugmaker.
A federal jury in Boston delivered a landmark verdict Monday, finding Takeda Pharmaceutical (搜索) liable for $885 million in damages for orchestrating an anticompetitive scheme that delayed generic competition for its constipation (搜索) medication Amitiza. The decision represents the first successful class action verdict against a pharmaceutical company over pay-for-delay agreements since the U.S. Supreme Court ruled such deals could violate antitrust law in 2013.
The jury sided with pharmacies, insurers, health funds and major retailers including CVS and Walgreens, who argued that Takeda's actions forced them to overpay for the drug over a six-year period. Under federal antitrust law, the $885 million award is subject to automatic tripling, potentially exposing the Japanese pharmaceutical giant to damages exceeding several billion dollars.
Historic Legal Victory
Monday's verdict breaks new ground in pharmaceutical antitrust litigation. "We were incredibly fortunate to have a committed jury that really showed up every day, took their job seriously," said Kristen Johnson, a lawyer representing drug purchasers in the class action. "They understood that paying off a competitor has real consequences on competition."
The decision stands in stark contrast to three previous trials involving similar pay-for-delay allegations, all of which ended in defense verdicts. The lawsuits, filed in 2021, are part of a broader wave of litigation targeting reverse payment agreements between brand-name and generic drugmakers.
The Amitiza Settlement Scheme
The case centered on Amitiza (lubiprostone), a constipation (搜索) medication originally developed by Sucampo Pharmaceuticals (搜索) and marketed in partnership with Takeda following FDA approval in 2006. The controversy began in 2012 when Par Pharmaceutical sought regulatory approval to launch a generic version of the drug.
Sucampo and Takeda responded by filing patent infringement lawsuits against Par, while the generic manufacturer countered that the patents were invalid. The companies reached a settlement in 2014 under which Par agreed to delay launching its generic version until January 2021. In exchange, Par received the right to sell an authorized generic version of Amitiza supplied by Sucampo under a 50-50 profit-sharing arrangement.
Plaintiffs' attorneys characterized the settlement as a $210 million "payoff" that eliminated generic competition for six years while providing Par with a lucrative partnership. Sucampo was subsequently acquired by Mallinckrodt in 2018.
Competing Legal Arguments
Takeda's defense team, led by attorney Joshua Barlow, argued during closing statements that the settlement was lawful and actually promoted competition. Barlow contended that without the agreement, generic Amitiza would still be unavailable because the final patents protecting the drug don't expire until October 2027.
"It increased competition," Barlow told jurors, maintaining that the settlement allowed for earlier generic entry than would have occurred through patent litigation.
However, the jury ultimately rejected this argument, finding that the arrangement constituted an illegal restraint on competition that harmed purchasers and consumers.
Damage Awards and Financial Impact
The jury awarded $474.9 million to direct purchasers including pharmacies and wholesalers, and $63.2 million to insurers and other end payers. Individual retailers that pursued separate claims received substantial awards, with CVS awarded $191 million and Walgreens receiving $121 million.
Takeda denied wrongdoing throughout the trial and is expected to challenge the verdict. The company's attorneys declined to comment following the jury's decision.
Broader Industry Implications
The verdict sends a strong signal to the pharmaceutical industry about the legal risks associated with pay-for-delay agreements. These arrangements, also known as reverse payment deals, have faced increasing scrutiny from federal regulators and class action attorneys who argue they artificially extend monopoly pricing for brand-name drugs.
The Supreme Court's 2013 decision in FTC v. Actavis established that such agreements could violate antitrust law, but Monday's verdict represents the first time a jury has held a pharmaceutical company liable in class action litigation under this legal framework.